RxSight, Inc. (RXST)

Options skew in RXST is leaning heavily bearish into the next rate cycle decision. Watching the 50-day moving average closely for an inflection.

From our Options Desk perspective, implied volatility on RXST is pricing in significant event risk following the Q2 earnings release. The combination of withdrawn guidance, a 9% drop in LAL unit volume to 24,917 units, and 12 LDD placements yielding $1.3 million creates a bifurcated narrative. Market makers are adjusting skews to account for potential choppy trading as the market digests the structural shift from standalone commercial growth toward the Alcon-partnered framework. We are advising structured collar strategies to protect long positions while the new management team completes its strategic review.

As a Hedge Fund Portfolio Manager tracking RXST, I am closely monitoring the withdrawal of full-year 2026 guidance by incoming CEO Aziz Mottiwala. While the core product sales dropping 19% year-over-year to $27.2 million is a clear yellow flag signaling increased competitive pressure, the financial cushion provided by the Alcon collaboration—injecting $6.5 million in Q2 and slated for $30M–$40M total in 2026—softens the blow. Paired with roughly $209 million in cash and short-term investments plus a subsequent $60 million upfront payment, the downside is heavily cushioned, making this a classic operational turnaround play if Mottiwala can stabilize core LAL adoption.

Looking at RXST through a quantitative Bio-Analyst lens, the valuation metrics present a fascinating NCAV-style setup. The company is trading at levels where its cash, short-term investments of $209 million, and the upcoming Alcon cash infusions form a robust floor beneath the enterprise. Even though Q2 net losses hit $12.1 million and product revenue contracted, the strategic collaboration to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses with Alcon alters the long-term total addressable market potential. The market's knee-jerk negative reaction to the lowered product sales forecast overlooks the broader structural de-risking of the balance sheet.

As a practicing Ophthalmic Clinician evaluating surgical tech platforms, our clinic is watching the Light Adjustable Lens (LAL) ecosystem very carefully. Despite the 19% year-over-year decline in core product sales and heightened competitive trialing reported this quarter, the underlying clinical utility of custom postoperative visual acuity adjustments remains strong. The installed base of Light Delivery Devices (LDD) standing at 1,166 units gives them a sticky footprint. However, management's focus needs to pivot firmly toward increasing utilization rates across this existing installed base rather than relying purely on rapid new unit placements.

From a small-cap momentum trader's viewpoint, RXST has hit an interim valuation floor. Historical patterns suggest that cash-rich, operationally distressed small caps often pivot effectively once new leadership conducts a thorough strategic review. The fact that LAL unit volume still reached 24,917 units despite marketplace headwinds proves there is an active, dedicated user base. If Mottiwala successfully strengthens sales execution and capitalizes on the Alcon partnership synergies, the stock offers an attractive risk-reward asymmetry for patient capital willing to ride out the near-term guidance vacuum.